Results 221 to 230 of about 564,426 (377)

Primary Bone Marrow Classic Hodgkin Lymphoma With Haemophagocytic Lymphohistiocytosis. [PDF]

EJHaem
Lee CT.
europepmc   +1 more source

A SURGICAL CASE OF NON-HODGKIN LYMPHOMA ORIGINATING FROM THE THYMUS

, 1993
Kiyohiro Fujiwara, Kazuo Yamabe, Masaharu HONDA, Noboru Nakano   +3 more
openalex   +2 more sources

Different age limits for elderly patients with indolent and aggressive non-Hodgkin lymphoma and the role of relative survival with increasing age [PDF]

, 2000
E. Maartense, Hanneke C. Kluin‐Nelemans, Saskia le Cessie, Philip M. Kluin, Simone Snijder, Evert M. Noordijk   +5 more
openalex   +1 more source

Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor–modified T cells

Science Translational Medicine, 2016
C. Turtle, L. Hanafi, C. Berger, M. Hudecek, B. Pender, E. Robinson, R. Hawkins, Colette N. Chaney, S. Cherian, Xueyan Chen, L. Soma, B. Wood, Daniel H. Li, S. Heimfeld, S. Riddell, D. Maloney   +15 more
semanticscholar   +1 more source

Frail is not fail: Limited impact of comorbidities on non‐relapse mortality and safety in patients with LBCL treated with CAR‐T

British Journal of Haematology, EarlyView.
We applied three major comorbidity scoring systems—CIRS, HCT‐CI, and Severe4—to a cohort of 379 patients with LBCL treated with CAR‐T therapy. A high comorbidity burden was identified in 7% to 34% of patients, depending on the score used. However, a high comorbidity burden did not negatively impact the tolerability of CAR‐T treatment, including the ...
Eugenio Galli, Roberta Di Blasi, Ilaria Pansini, Caterina Cristinelli, Come Bommier, Ilenia De Bernardis, Alessandro Corrente, Marcello Viscovo, Luca Montini, Patrizia Chiusolo, Stefan Hohaus, Federica Sorà, Catherine Thieblemont, Simona Sica   +13 more
wiley   +1 more source

GVHD in the era of checkpoint inhibition in Hodgkin lymphoma. [PDF]

Blood Adv
Fidanza CA, Serpenti F, Cavallaro F, Barbullushi K, Rampi N, Rossi Dardanoni FG, Goldaniga M, Saporiti GN, Passamonti F.   +8 more
europepmc   +1 more source

16 cases of non-Hodgkin Lymphoma with Newly Designed Therapy.

, 1993
Satoko Nakamura, Tatsuo Shiigai
openalex   +2 more sources

Prognostic factors and treatment outcome in primary progressive Hodgkin lymphoma: a report from the German Hodgkin Lymphoma Study Group [PDF]

, 2000
Andreas Josting, U. Rueffer, Jeremy Franklin, Markus Sieber, Volker Diehl, Andreas Engert   +5 more
openalex   +1 more source

Secondary malignancies after chronic myeloid leukaemia upon TKI treatment: Population trends and outcomes

British Journal of Haematology, EarlyView.
A retrospective study from 11 institutions was performed in 139 chronic myeloid leukaemia (CML) patients with secondary malignancies. The median ages at diagnosis of CML and secondary malignancy were 51 years (range, 13–88 years) and 53 years (range, 18–91 years). After a median follow‐up of 85 months, the median time from diagnosis of CML to secondary
Yingling Zu, Xipeng Yue, Xinrong Zhan, Xiaojuan Liu, Hongxia Ma, Fuli Qin, Lijuan Duan, Hongmian Zhao, Yan Zhang, Shiqiang He, Huifang Zhao, Chunlei Zhang, Xiangke Xin, Wenli Zhang, Yongping Song, Bingcheng Liu, Weiming Li, Yanli Zhang   +17 more
wiley   +1 more source

Predicting thrombotic risk in patients with classical Hodgkin lymphoma: Thro-HL multicenter study. [PDF]

Hemasphere
Assanto GM, Alma E, Cellini A, Marsili G, Maiorana G, Santoro C, Salvatori M, Cenfra N, Otasevic V, Antic D, D'Elia GM, Bianchi MP, Annechini G, Ligia S, Pulsoni A, Tafuri A, Visentin A, Piciocchi A, Hohaus S, Martelli M, Del Giudice I, Chistolini A.   +21 more
europepmc   +1 more source